Cell + Gene Therapies Webinar: IP Due Diligence

Michael Shuster, Joshua Weinger, and Sarah Stoiber will host the Cell + Gene Therapies Webinar: IP Due Diligence on September 18th. 

In the rapidly evolving field of cell and gene therapies, when millions of dollars or even entire businesses are at stake, IP due diligence is essential to determining the total value of the IP involved, assessing and evaluating the risks, and ensuring the transaction is in each party's best interests. Whether securing investment, advancing your technology, or preparing for potential disputes, effective IP due diligence is not just a safeguard; it's a promise of long-term success. It's the key to ensuring your innovations are protected and your future is secure. 

Webinar Highlights: 

• Understanding Key Challenges: Explore the unique IP issues faced by cell and gene therapies companies, including patentability, freedom-to-operate, and managing third-party risks. 
• Best Practices in IP Due Diligence: Learn how to conduct thorough and strategic IP reviews at your company's growth stages, from early investment rounds to pre-litigation planning. 
• Case Studies and Real-World Insights: This is not just theory but practical knowledge that you can apply in your work. Gain insights from industry experts who will share practical examples and lessons learned from working with leading companies in the life sciences sector.